MD Anderson is renowned for breakthrough discoveries and exceptional patient care. Our research enterprise is rooted in interdisciplinary collaboration, benefiting patients faster than ever through our expansive clinical trials program. Our work has led to new treatments such as CAR T cell therapy, eliminated the need for chemotherapy for some leukemia patients and improved outcomes for stem cell transplant patients.
At the ASH Annual Meeting and Exposition, our experts showcase their latest practice-changing work with colleagues from across the globe for large-scale discussion.
Keep up with presentation highlights from our experts as well as learn more about our pioneering research across the field of hematology below.
Novel drug combinations and targeted therapies show promise for patients with leukemia
Oral presentations from Naval Daver, M.D., , Nicholas Short, M.D., and Patrick Reville, M.D., highlight encouraging results that may improve treatment of multiple types of leukemia, including high-risk and newly diagnosed acute myeloid leukemia in older and younger patients and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations
Ghayas Issa, M.D., to present updated results from AUGMENT-101 clinical trial
MD Anderson Research Highlights: ASH 2022 Special Edition
Key presentations showcase innovative targeted therapies, new combination approaches and novel targets to improve outcomes for patients with leukemias, Hodgkin lymphoma, non-Hodgkin lymphoma, myeloma and other hematologic cancers.
Meet the Experts
Stop by booth 2219 to ask a question, learn about training and career opportunities and continue the conversation on key presentations with our experts.
Saturday, Dec. 10
Ferran Prat, Ph.D.
Senior Vice President, Research Administration and Industry Relations
Christopher Flowers, M.D.
Division Head ad interim, Cancer Medicine and Chair, Lymphoma and Myeloma
Sunday, Dec. 11
Monday, Dec. 12
Philip Jones, Ph.D.
Vice President, Therapeutics Discovery and Head of Drug Discovery, The Institute for Applied Cancer Science
James P. Allison Institute
The James P. Allison Institute is dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health. The institute builds upon the legacy of its namesake, James P. Allison, Ph.D., who was awarded the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer.
As America's fourth largest city, Houston has a lot to offer. Find out why Houston is a hub for scientific and medical excellence.
Education and Training at MD Anderson
MD Anderson academic programs are competitive and comprehensive. We offer educational opportunities from undergraduate degrees to graduate medical education opportunities.